SEC alleges insider trading ahead of Onyx Pharmaceuticals rejection of Amgen buyout bid

  • Updated: July 3, 2013 - 6:55 PM

NEW YORK — The Securities and Exchange Commission on Friday accused unnamed traders of raking in approximately $4.6 million in potentially illegal profits by using foreign accounts to trade on inside knowledge of a buyout offer for drugmaker Onyx Pharmaceuticals Inc.

ADVERTISEMENT

Connect with twitterConnect with facebookConnect with Google+Connect with PinterestConnect with PinterestConnect with RssfeedConnect with email newsletters

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT